Targeting NEK2 as a promising therapeutic approach for cancer treatment

References

• Fry AM, O'Regan L, Sabir SR, Bayliss R. Cell cycle regulation by the NEK family of protein kinases. J Cell Sci 2012; 125:4423-33; PMID:23132929; http://dx.doi.org/10.1242/jcs.111195
   PubMed Web of Science ®Google Scholar
• Schultz SJ, Fry AM, Sutterlin C, Ried T, Nigg EA. Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans. Cell Growth Differ 1994; 5:625-35; PMID:7522034
   PubMedGoogle Scholar
• Hames RS, Fry AM. Alternative splice variants of the human centrosome kinase Nek2 exhibit distinct patterns of expression in mitosis. Biochem J 2002; 361:77-85; PMID:11742531; http://dx.doi.org/10.1042/bj3610077
   PubMed Web of Science ®Google Scholar
• Wu W, Baxter JE, Wattam SL, Hayward DG, Fardilha M, Knebel A, Ford EM, da Cruz e Silva EF, Fry AM. Alternative splicing controls nuclear translocation of the cell cycle-regulated Nek2 kinase. J Biol Chem 2007; 282:26431-40; PMID:17626005; http://dx.doi.org/10.1074/jbc.M704969200
   PubMed Web of Science ®Google Scholar
• Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett 2006; 237:155-66; PMID:16084011; http://dx.doi.org/10.1016/j.canlet.2005.06.017
   PubMed Web of Science ®Google Scholar
• Fry AM, Meraldi P, Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J 1998; 17:470-81; PMID:9430639; http://dx.doi.org/10.1093/emboj/17.2.470
   PubMed Web of Science ®Google Scholar
• Faragher AJ, Fry AM. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell 2003; 14:2876-89; PMID:12857871; http://dx.doi.org/10.1091/mbc.E03-02-0108
   PubMed Web of Science ®Google Scholar
• Jeong Y, Lee J, Kim K, Yoo JC, Rhee K. Characterization of NIP2/centrobin, a novel substrate of Nek2, and its potential role in microtubule stabilization. J Cell Sci 2007; 120:2106-16; PMID:17535851; http://dx.doi.org/10.1242/jcs.03458
   PubMed Web of Science ®Google Scholar
• Sonn S, Jeong Y, Rhee K. Nip2/centrobin may be a substrate of Nek2 that is required for proper spindle assembly during mitosis in early mouse embryos. Mol Reprod Dev 2009; 76:587-92; PMID:19117032; http://dx.doi.org/10.1002/mrd.20990
   PubMed Web of Science ®Google Scholar
• Chen Y, Riley DJ, Zheng L, Chen PL, Lee WH. Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem 2002; 277:49408-16; PMID:12386167; http://dx.doi.org/10.1074/jbc.M207069200
   PubMed Web of Science ®Google Scholar
• Du J, Cai X, Yao J, Ding X, Wu Q, Pei S, Jiang K, Zhang Y, Wang W, Shi Y, et al. The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability. Oncogene 2008; 27:4107-14; PMID:18297113; http://dx.doi.org/10.1038/onc.2008.34
   PubMed Web of Science ®Google Scholar
• Lou Y, Yao J, Zereshki A, Dou Z, Ahmed K, Wang H, Hu J, Wang Y, Yao X. NEK2A interacts with MAD1 and possibly functions as a novel integrator of the spindle checkpoint signaling. J Biol Chem 2004; 279:20049-57; PMID:14978040; http://dx.doi.org/10.1074/jbc.M314205200
   PubMed Web of Science ®Google Scholar
• Wei R, Ngo B, Wu G, Lee WH. Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell 2011; 22:3584-94; PMID:21832156; http://dx.doi.org/10.1091/mbc.E11-01-0012
   PubMed Web of Science ®Google Scholar
• Fu G, Ding X, Yuan K, Aikhionbare F, Yao J, Cai X, Jiang K, Yao X. Phosphorylation of human Sgo1 by NEK2A is essential for chromosome congression in mitosis. Cell Res 2007; 17:608-18; PMID:17621308; http://dx.doi.org/10.1038/cr.2007.55
   PubMed Web of Science ®Google Scholar
• Fry AM, Schultz SJ, Bartek J, Nigg EA. Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of Aspergillus nidulans. J Biol Chem 1995; 270:12899-905; PMID:7759549; http://dx.doi.org/10.1074/jbc.270.47.28357
   PubMed Web of Science ®Google Scholar
• Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002; 16:245-56; PMID:11799067; http://dx.doi.org/10.1101/gad.949802
   PubMed Web of Science ®Google Scholar
• Nabilsi NH, Ryder DJ, Peraza-Penton AC, Poudyal R, Loose DS, Kladde MP. Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter. J Biol Chem 2013; 288:35940-51; PMID:24163369; http://dx.doi.org/10.1074/jbc.M113.523837
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Iwaya T, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Takano Y, Eguchi H, Sudo T, et al. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. Ann Surg Oncol 2014; 21:205-12; PMID:24046120; http://dx.doi.org/10.1245/s10434-013-3264-3
   PubMed Web of Science ®Google Scholar
• Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7:126-36; PMID:15654331; http://dx.doi.org/10.1038/ncb1217
   PubMed Web of Science ®Google Scholar
• Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005; 65:5181-9; PMID:15958562; http://dx.doi.org/10.1158/0008-5472.CAN-04-4059
   PubMed Web of Science ®Google Scholar
• Hames RS, Wattam SL, Yamano H, Bacchieri R, Fry AM. APC/C-mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A-type D-box. EMBO J 2001; 20:7117-27; PMID:11742988; http://dx.doi.org/10.1093/emboj/20.24.7117
   PubMed Web of Science ®Google Scholar
• Hames RS, Crookes RE, Straatman KR, Merdes A, Hayes MJ, Faragher AJ, Fry AM. Dynamic recruitment of Nek2 kinase to the centrosome involves microtubules, PCM-1, and localized proteasomal degradation. Mol Biol Cell 2005; 16:1711-24; PMID:15659651; http://dx.doi.org/10.1091/mbc.E04-08-0688
   PubMed Web of Science ®Google Scholar
• Sedgwick GG, Hayward DG, Di Fiore B, Pardo M, Yu L, Pines J, Nilsson J. Mechanisms controlling the temporal degradation of Nek2A and Kif18A by the APC/C-Cdc20 complex. EMBO J 2013; 32:303-14; PMID:23288039; http://dx.doi.org/10.1038/emboj.2012.335
   PubMed Web of Science ®Google Scholar
• Fry AM, Arnaud L, Nigg EA. Activity of the human centrosomal kinase, Nek2, depends on an unusual leucine zipper dimerization motif. J Biol Chem 1999; 274:16304-10; PMID:10347187; http://dx.doi.org/10.1074/jbc.274.23.16304
   PubMed Web of Science ®Google Scholar
• Rellos P, Ivins FJ, Baxter JE, Pike A, Nott TJ, Parkinson DM, Das S, Howell S, Fedorov O, Shen QY, et al. Structure and regulation of the human Nek2 centrosomal kinase. J Biol Chem 2007; 282:6833-42; PMID:17197699; http://dx.doi.org/10.1074/jbc.M609721200
   PubMed Web of Science ®Google Scholar
• Di Agostino S, Rossi P, Geremia R, Sette C. The MAPK pathway triggers activation of Nek2 during chromosome condensation in mouse spermatocytes. Development 2002; 129:1715-27; PMID:11923207
   PubMed Web of Science ®Google Scholar
• Helps NR, Luo X, Barker HM, Cohen PT. NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase localized to centrosomes, is complexed to protein phosphatase 1. Biochem J 2000; 349:509-18; PMID:10880350; http://dx.doi.org/10.1042/bj3490509
   PubMed Web of Science ®Google Scholar
• Fry AM, Mayor T, Meraldi P, Stierhof YD, Tanaka K, Nigg EA. C-Nap1, a novel centrosomal coiled-coil protein and candidate substrate of the cell cycle-regulated protein kinase Nek2. J Cell Biol 1998; 141:1563-74; PMID:9647649; http://dx.doi.org/10.1083/jcb.141.7.1563
   PubMed Web of Science ®Google Scholar
• Bahe S, Stierhof YD, Wilkinson CJ, Leiss F, Nigg EA. Rootletin forms centriole-associated filaments and functions in centrosome cohesion. J Cell Biol 2005; 171:27-33; PMID:16203858; http://dx.doi.org/10.1083/jcb.200504107
   PubMed Web of Science ®Google Scholar
• Man X, Megraw TL, Lim YP. Cep68 can be regulated by Nek2 and SCF complex. Eur J Cell Biol 2015; 94:162-72; PMID:25704143; http://dx.doi.org/10.1016/j.ejcb.2015.01.004
   PubMed Web of Science ®Google Scholar
• Rapley J, Baxter JE, Blot J, Wattam SL, Casenghi M, Meraldi P, Nigg EA, Fry AM. Coordinate regulation of the mother centriole component nlp by nek2 and plk1 protein kinases. Mol Cell Biol 2005; 25:1309-24; PMID:15684383; http://dx.doi.org/10.1128/MCB.25.4.1309-1324.2005
   PubMed Web of Science ®Google Scholar
• Park J, Rhee K. NEK2 phosphorylation antagonizes the microtubule stabilizing activity of centrobin. Biochem Biophys Res Commun 2013; 431:302-8; PMID:23291182; http://dx.doi.org/10.1016/j.bbrc.2012.12.106
   PubMed Web of Science ®Google Scholar
• Di Agostino S, Fedele M, Chieffi P, Fusco A, Rossi P, Geremia R, Sette C. Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. Mol Biol Cell 2004; 15:1224-32; PMID:14668482; http://dx.doi.org/10.1091/mbc.E03-09-0638
   PubMed Web of Science ®Google Scholar
• Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G, Zhan F. Nek2 is a novel regulator of B cell development and immunological response. Biomed Res Int 2014; 2014:621082; PMID:25485281
   PubMed Web of Science ®Google Scholar
• Kim S, Lee K, Choi JH, Ringstad N, Dynlacht BD. Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle. Nat Commun 2015; 6:8087; PMID:26290419; http://dx.doi.org/10.1038/ncomms9087
   PubMed Web of Science ®Google Scholar
• Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T, Boecker W, Schweigerer L, Dockhorn-Dworniczak B, Poremba C. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 2002; 20:441-51; PMID:11836553
   PubMed Web of Science ®Google Scholar
• de Vos S, Hofmann WK, Grogan TM, Krug U, Schrage M, Miller TP, Braun JG, Wachsman W, Koeffler HP, Said JW. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003; 83:271-85; PMID:12594241; http://dx.doi.org/10.1097/01.LAB.0000053913.85892.E9
   PubMed Web of Science ®Google Scholar
• Andreasson U, Dictor M, Jerkeman M, Berglund M, Sundstrom C, Linderoth J, Rosenquist R, Borrebaeck CA, Ek S. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. Am J Hematol 2009; 84:803-8; PMID:19844990; http://dx.doi.org/10.1002/ajh.21549
   PubMed Web of Science ®Google Scholar
• Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res 2004; 64:7370-6; PMID:15492258; http://dx.doi.org/10.1158/0008-5472.CAN-04-0960
   PubMed Web of Science ®Google Scholar
• Tsunoda N, Kokuryo T, Oda K, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci 2009; 100:111-6; PMID:19038001; http://dx.doi.org/10.1111/j.1349-7006.2008.01007.x
   PubMed Web of Science ®Google Scholar
• Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013; 23:48-62; PMID:23328480; http://dx.doi.org/10.1016/j.ccr.2012.12.001
   PubMed Web of Science ®Google Scholar
• Cappello P, Blaser H, Gorrini C, Lin DC, Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA, et al. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene 2014; 33:2375-84; PMID:23708664; http://dx.doi.org/10.1038/onc.2013.183
   PubMed Web of Science ®Google Scholar
• Koch M, Wiese M. Gene expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancer. J Cancer Res Clin Oncol 2013; 139:259-67; PMID:23052694; http://dx.doi.org/10.1007/s00432-012-1317-9
   PubMed Web of Science ®Google Scholar
• Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep 2014; 31:745-54; PMID:24337664
   PubMed Web of Science ®Google Scholar
• Zeng YR, Han ZD, Wang C, Cai C, Huang YQ, Luo HW, Liu ZZ, Zhuo YJ, Dai QS, Zhao HB, et al. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer. BMC Urol 2015; 15:90; PMID:26320076; http://dx.doi.org/10.1186/s12894-015-0085-7
   PubMed Web of Science ®Google Scholar
• Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res 2007; 67:9637-42; PMID:17942892; http://dx.doi.org/10.1158/0008-5472.CAN-07-1489
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci 2010; 101:1163-9; PMID:20345485; http://dx.doi.org/10.1111/j.1349-7006.2010.01504.x
   PubMed Web of Science ®Google Scholar
• Neal CP, Fry AM, Moreman C, McGregor A, Garcea G, Berry DP, Manson MM. Overexpression of the Nek2 kinase in colorectal cancer correlates with beta-catenin relocalization and shortened cancer-specific survival. J Surg Oncol 2014; 110:828-38; PMID:25043295; http://dx.doi.org/10.1002/jso.23717
   PubMed Web of Science ®Google Scholar
• Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ. Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. Cancer Sci 2010; 101:2316-24; PMID:20718755; http://dx.doi.org/10.1111/j.1349-7006.2010.01694.x
   PubMed Web of Science ®Google Scholar
• Barbagallo F, Paronetto MP, Franco R, Chieffi P, Dolci S, Fry AM, Geremia R, Sette C. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol 2009; 217:431-41; PMID:19023884; http://dx.doi.org/10.1002/path.2471
   PubMed Web of Science ®Google Scholar
• Stricker TP, Henriksen KJ, Tonsgard JH, Montag AG, Krausz TN, Pytel P. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol 2013; 26:930-43; PMID:23370767; http://dx.doi.org/10.1038/modpathol.2012.242
   PubMed Web of Science ®Google Scholar
• Ning Z, Wang A, Liang J, Liu J, Zhou T, Yan Q, Wang Z. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. Int J Clin Exp Pathol 2014; 7:2462-9; PMID:24966957
   PubMed Web of Science ®Google Scholar
• Zhang MX, Xu XM, Zhang P, Han NN, Deng JJ, Yu TT, Gan YY, He XQ, Long ZX. Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway. Tumour Biol 2015
   Google Scholar
• Zhong X, Guan X, Dong Q, Yang S, Liu W, Zhang L. Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis. Tumour Biol 2014; 35:7155-62; PMID:24763826; http://dx.doi.org/10.1007/s13277-014-1935-8
   PubMed Web of Science ®Google Scholar
• Bidkhori G, Narimani Z, Hosseini Ashtiani S, Moeini A, Nowzari-Dalini A, Masoudi-Nejad A. Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma. PLoS One 2013; 8:e67552; PMID:23874428; http://dx.doi.org/10.1371/journal.pone.0067552
   PubMed Web of Science ®Google Scholar
• Harrison Pitner MK, Saavedra HI. Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model. PLoS One 2013; 8:e65971; PMID:23776583; http://dx.doi.org/10.1371/journal.pone.0065971
   PubMed Web of Science ®Google Scholar
• Lee J, Gollahon L. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells. Cell Cycle 2013; 12:3599-614; PMID:24091727; http://dx.doi.org/10.4161/cc.26589
   PubMed Web of Science ®Google Scholar
• Lee J, Gollahon L. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triplenegative breast cancer cells. Int J Oncol 2013; 42:839-47; PMID:23340795
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget 2014; 5:11986-97; PMID:25230277; http://dx.doi.org/10.18632/oncotarget.2388
   PubMed Web of Science ®Google Scholar
• Marina M, Saavedra HI. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed) 2014; 19:352-65; PMID:24389189; http://dx.doi.org/10.2741/4212
   PubMed Web of Science ®Google Scholar
• Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008; 14:2601-8; PMID:18451222; http://dx.doi.org/10.1158/1078-0432.CCR-07-5026
   PubMed Web of Science ®Google Scholar
• Liu X. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Transl Oncol 2015; 8:185-95; PMID:26055176; http://dx.doi.org/10.1016/j.tranon.2015.03.010
   PubMed Web of Science ®Google Scholar
• Mardin BR, Agircan FG, Lange C, Schiebel E. Plk1 controls the Nek2A-PP1gamma antagonism in centrosome disjunction. Curr Biol 2011; 21:1145-51; PMID:21723128; http://dx.doi.org/10.1016/j.cub.2011.05.047
   PubMed Web of Science ®Google Scholar
• Mardin BR, Lange C, Baxter JE, Hardy T, Scholz SR, Fry AM, Schiebel E. Components of the Hippo pathway cooperate with Nek2 kinase to regulate centrosome disjunction. Nat Cell Biol 2010; 12:1166-76; PMID:21076410; http://dx.doi.org/10.1038/ncb2120
   PubMed Web of Science ®Google Scholar
• Mbom BC, Siemers KA, Ostrowski MA, Nelson WJ, Barth AI. Nek2 phosphorylates and stabilizes beta-catenin at mitotic centrosomes downstream of Plk1. Mol Biol Cell 2014; 25:977-91; PMID:24501426; http://dx.doi.org/10.1091/mbc.E13-06-0349
   PubMed Web of Science ®Google Scholar
• Khanna A, Pimanda JE, Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 2013; 73:6548-53; PMID:24204027; http://dx.doi.org/10.1158/0008-5472.CAN-13-1994
   PubMed Web of Science ®Google Scholar
• Jeong AL, Lee S, Park JS, Han S, Jang CY, Lim JS, Lee MS, Yang Y. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity. J Biol Chem 2014; 289:28-40; PMID:24214971; http://dx.doi.org/10.1074/jbc.M113.507954
   PubMed Web of Science ®Google Scholar
• Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014; 20:3379-83; PMID:24795392; http://dx.doi.org/10.1158/1078-0432.CCR-13-1551
   PubMed Web of Science ®Google Scholar
• Adon AM, Zeng X, Harrison MK, Sannem S, Kiyokawa H, Kaldis P, Saavedra HI. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol 2010; 30:694-710; PMID:19933848; http://dx.doi.org/10.1128/MCB.00253-09
   PubMed Web of Science ®Google Scholar
• Liu Q, Hirohashi Y, Du X, Greene MI, Wang Q. Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism for aneuploidy in cancer. Exp Mol Pathol 2010; 88:225-33; PMID:20034488; http://dx.doi.org/10.1016/j.yexmp.2009.12.004
   PubMed Web of Science ®Google Scholar
• Walker JR, Zhu XD. Post-translational modifications of TRF1 and TRF2 and their roles in telomere maintenance. Mech Ageing Dev 2012; 133:421-34; PMID:22634377; http://dx.doi.org/10.1016/j.mad.2012.05.002
   PubMed Web of Science ®Google Scholar
• Ohishi T, Muramatsu Y, Yoshida H, Seimiya H. TRF1 ensures the centromeric function of Aurora-B and proper chromosome segregation. Mol Cell Biol 2014; 34:2464-78; PMID:24752893; http://dx.doi.org/10.1128/MCB.00161-14
   PubMed Web of Science ®Google Scholar
• Prime G, Markie D. The telomere repeat binding protein Trf1 interacts with the spindle checkpoint protein Mad1 and Nek2 mitotic kinase. Cell Cycle 2005; 4:121-4; PMID:15611654; http://dx.doi.org/10.4161/cc.4.1.1351
   PubMed Web of Science ®Google Scholar
• Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303:1483-7; PMID:15001769; http://dx.doi.org/10.1126/science.1094291
   PubMed Web of Science ®Google Scholar
• Kaplan DD, Meigs TE, Kelly P, Casey PJ. Identification of a role for beta-catenin in the establishment of a bipolar mitotic spindle. J Biol Chem 2004; 279:10829-32; PMID:14744872; http://dx.doi.org/10.1074/jbc.C400035200
   PubMed Web of Science ®Google Scholar
• Bahmanyar S, Kaplan DD, Deluca JG, Giddings TH, Jr., O'Toole ET, Winey M, Salmon ED, Casey PJ, Nelson WJ, Barth AI. beta-Catenin is a Nek2 substrate involved in centrosome separation. Genes Dev 2008; 22:91-105; PMID:18086858; http://dx.doi.org/10.1101/gad.1596308
   PubMed Web of Science ®Google Scholar
• Wang S, Li W, Lv S, Wang Y, Liu Z, Zhang J, Liu T, Niu Y. Abnormal expression of Nek2 and beta-catenin in breast carcinoma: clinicopathological correlations. Histopathology 2011; 59:631-42; PMID:22014044; http://dx.doi.org/10.1111/j.1365-2559.2011.03941.x
   PubMed Web of Science ®Google Scholar
• Das TK, Dana D, Paroly SS, Perumal SK, Singh S, Jhun H, Pendse J, Cagan RL, Talele TT, Kumar S. Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis. Oncogenesis 2013; 2:e69; PMID:24018644; http://dx.doi.org/10.1038/oncsis.2013.34
   PubMed Web of Science ®Google Scholar
• Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 2015; PMID:26300000
   PubMed Web of Science ®Google Scholar
• Naro C, Barbagallo F, Chieffi P, Bourgeois CF, Paronetto MP, Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res 2014; 42:3218-27; PMID:24369428; http://dx.doi.org/10.1093/nar/gkt1307
   PubMed Web of Science ®Google Scholar
• Emmitte KA, Adjabeng GM, Andrews CW, Alberti JG, Bambal R, Chamberlain SD, Davis-Ward RG, Dickson HD, Hassler DF, Hornberger KR, et al. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett 2009; 19:1694-7; PMID:19237286; http://dx.doi.org/10.1016/j.bmcl.2009.01.094
   PubMed Web of Science ®Google Scholar
• Hayward DG, Newbatt Y, Pickard L, Byrne E, Mao G, Burns S, Sahota NK, Workman P, Collins I, Aherne W, et al. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated nek2 kinase. J Biomol Screen 2010; 15:918-27; PMID:20664067; http://dx.doi.org/10.1177/1087057110376537
   PubMed Web of Science ®Google Scholar
• Whelligan DK, Solanki S, Taylor D, Thomson DW, Cheung KM, Boxall K, Mas-Droux C, Barillari C, Burns S, Grummitt CG, et al. Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem 2010; 53:7682-98; PMID:20936789; http://dx.doi.org/10.1021/jm1008727
   PubMed Web of Science ®Google Scholar
• Solanki S, Innocenti P, Mas-Droux C, Boxall K, Barillari C, van Montfort RL, Aherne GW, Bayliss R, Hoelder S. Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (Nek2) without binding to the back pocket and reveal a nonlinear structure-activity relationship. J Med Chem 2011; 54:1626-39; PMID:21366329; http://dx.doi.org/10.1021/jm1011726
   PubMed Web of Science ®Google Scholar
• Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, et al. Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity. J Med Chem 2012; 55:3228-41; PMID:22404346; http://dx.doi.org/10.1021/jm201683b
   PubMed Web of Science ®Google Scholar
• Henise JC, Taunton J. Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem 2011; 54:4133-46; PMID:21627121; http://dx.doi.org/10.1021/jm200222m
   PubMed Web of Science ®Google Scholar
• Carbain B, Bayliss R, Boxall K, Coxon C, Lebraud H, Matheson C, Turner D, Zhen-Wang L, Griffin RJ. 118 2-arylamino-6-ethynylpurines as Potent Irreversible Inhibitors of the Mitotic Kinase Nek2. Eur J Cancer 2012; 48, Supplement 6:37; PMID:21664123; http://dx.doi.org/10.1016/S0959-8049(12)71916-0
   PubMed Web of Science ®Google Scholar
• Lebraud H, Coxon CR, Archard VS, Bawn CM, Carbain B, Matheson CJ, Turner DM, Cano C, Griffin RJ, Hardcastle IR, et al. Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles. Org Biomol Chem 2014; 12:141-8; PMID:24213855; http://dx.doi.org/10.1039/C3OB41806E
   PubMed Web of Science ®Google Scholar
• Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R, Lau J, Chen PL, Lee WH. Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res 2008; 68:8393-9; PMID:18922912; http://dx.doi.org/10.1158/0008-5472.CAN-08-1915
   PubMed Web of Science ®Google Scholar
• Qiu XL, Li G, Wu G, Zhu J, Zhou L, Chen PL, Chamberlin AR, Lee WH. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. J Med Chem 2009; 52:1757-67; PMID:19243176; http://dx.doi.org/10.1021/jm8015969
   PubMed Web of Science ®Google Scholar
• Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, et al. Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism. Oncogene 2015; 34:1220-30; PMID:24662830; http://dx.doi.org/10.1038/onc.2014.67
   PubMed Web of Science ®Google Scholar
• Huang LY, Lee YS, Huang JJ, Chang CC, Chang JM, Chuang SH, Kao KJ, Tsai YJ, Tsai PY, Liu CW, et al. Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1. J Exp Clin Cancer Res 2014; 33:6; PMID:24401611; http://dx.doi.org/10.1186/1756-9966-33-6
   PubMed Web of Science ®Google Scholar
• Huang LY, Chang CC, Lee YS, Chang JM, Huang JJ, Chuang SH, Kao KJ, Lau GM, Tsai PY, Liu CW, et al. Activity of a novel Hec1-targeted anticancer compound against breast cancer cell lines in vitro and in vivo. Mol Cancer Ther 2014; 13:1419-30; PMID:24694948; http://dx.doi.org/10.1158/1535-7163.MCT-13-0700
   PubMed Web of Science ®Google Scholar
• Huang LY, Chang CC, Lee YS, Huang JJ, Chuang SH, Chang JM, Kao KJ, Lau GM, Tsai PY, Liu CW, et al. Inhibition of Hec1 as a novel approach for treatment of primary liver cancer. Cancer Chemother Pharmacol 2014; 74:511-20; PMID:25038613; http://dx.doi.org/10.1007/s00280-014-2540-7
   PubMed Web of Science ®Google Scholar
• Lee YS, Chuang SH, Huang LY, Lai CL, Lin YH, Yang JY, Liu CW, Yang SC, Lin HS, Chang CC, et al. Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties. J Med Chem 2014; 57:4098-110; PMID:24773549; http://dx.doi.org/10.1021/jm401990s
   PubMed Web of Science ®Google Scholar